Global Hyperkalemia Treatment Market Research Report 2022

Hyperkalemia is a diseases in which levels of potassium are higher than normal level (3.5 and 5.0 mmol/L) in blood serum. Kidneys are responsible for managing potassium balance in the body by regulating its excretion as well as its intake. A person is prone to develop hyperkalemia when the consumption of potassium exceeds that of kidneys’ potential to excrete it. The right amount of potassium and sodium in the body play a vital role in normal functioning of the myocardium.

Hyperkalemia can occur due to congestive heart failure, chronic kidney disease, or diabetic kidney disease. The condition can also occur when a patient receives renin-angiotensin-aldosterone system inhibitors (RAAS) in kidney disease. Abnormal levels of potassium can lead to irregular heartbeats, which can be fatal. Hyperkalemia is diagnosed by kidney functioning test, creatinine blood test, blood tests, and glucose monitoring.
Due to the COVID-19 pandemic, the global Hyperkalemia Treatment market size is estimated to be worth US$ 540 million in 2021 and is forecast to a readjusted size of US$ 2068.8 million by 2028 with a CAGR of 20.9% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Hyperkalemia Treatment market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Hyperkalemia Treatment landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The main manufacturers of Global Hyperkalemia Treatment include Vifor Pharma, Astrazeneca, etc. These top two manufacturers hold a market share about 50%. North America and Europe are the major producing regions in the world.
This report focuses on Hyperkalemia Treatment volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Hyperkalemia Treatment market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America and Europe., etc.
Global Hyperkalemia Treatment Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Distribution Channel. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Patiromer
Sodium Zirconium Cyclosilicate
Segment by Distribution Channel
Hospital Pharmacy
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Chinese Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Vifor Pharma
Astrazeneca
Sanofi
CMP Pharma
Belcher Pharmaceuticals